Trial Profile
A Phase 2 Study With Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Patients With Microsatellite Stable Refractory Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 17 Sep 2018 Status changed from active, no longer recruiting to completed.
- 05 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Oct 2017.
- 20 Jul 2017 Status changed from recruiting to active, no longer recruiting.